Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β

Alzheimer's Research and Therapy

Volumn 6, Issue 2, 2014, Pages

  Toyn, Jeremy H ^a   Ahlijanian, Michael K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; BAPINEUZUMAB; BEGACESTAT; GAMMA SECRETASE; IMMUNOGLOBULIN G; PRESENILIN; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE DOSAGE; GENOTYPE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RISK FACTOR;

EID: 84898728701     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt244     Document Type: Article

References (128)

1. A Wimo, M Prince, World Alzheimer Report 2010: the Global Economic Impact of Dementia [ http://www.alz.org/documents/national/world-alzheimer-report- 2010.pdf ]
2. The role of amyloid β peptide 42 in Alzheimer's disease. MA Findeis, Pharmacol Therapeut 2007 116 266 286 10.1016/j.pharmthera.2007.06.006 (Pubitemid 47451506)
3. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. J Hardy, DJ Selkoe, Science 2002 297 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
4. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. E Karran, M Mercken, B De Strooper, Nat Rev Drug Disc 2011 10 698 712 10.1038/nrd3505
5. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. A Rovelet-Lecrux, D Hannequin, G Raux, N Le Meur, A Laquerrière, A Vital, C Dumanchin, S Feuillette, A Brice, M Vercelletto, F Dubas, T Frebourg, D Campion, Nat Genet 2006 38 24 26 10.1038/ng1718 16369530 (Pubitemid 43011878)
6. Down's syndrome: up-regulation of β-amyloid protein precursor and τ mRNAs and their defective coordination. F Oyama, NJ Cairns, H Shimada, R Oyama, K Titani, Y Ihara, J Neurochem 1994 62 1062 1066 8113792 (Pubitemid 24064519)
7. Decreased clearance of CNS β-amyloid in Alzheimer's disease. KG Mawuenyega, W Sigurdson, V Ovod, L Munsell, T Kasten, JC Morris, KE Yarasheski, RJ Bateman, Science 2010 330 1774 10.1126/science.1197623 21148344
8. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. T Jonsson, JK Atwal, S Steinberg, J Snaedal, PV Jonsson, S Bjornsson, H Stefansson, P Sulem, D Gudbjartsson, J Maloney, K Hoyte, A Gustafson, Y Liu, Y Lu, T Bhangale, RR Graham, J Huttenlocher, G Bjornsdottir, OA Andreassen, EG Jönsson, A Palotie, TW Behrens, OT Magnusson, A Kong, U Thorsteinsdottir, RJ Watts, K Stefansson, Nature 2012 488 96 99 10.1038/nature11283 22801501
9. Mean age-of-onset in familial Alzheimer's disease is determined by amyloid beta 42. M Duering, MO Grimm, HS Grimm, J Schröder, T Hartmann, Neurobiol Aging 2005 26 785 788 10.1016/j.neurobiolaging.2004.08.002 15718035 (Pubitemid 40249479)
10. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40. S Kumar-Singh, J Theuns, B Van Broeck, D Pirici, K Vennekens, E Corsmit, M Cruts, B Dermaut, R Wang, C Van Broeckhoven, Hum Mutat 2006 27 686 695 10.1002/humu.20336 16752394
11. Decreased Aβ secretase by cells expressing familial Alzheimer's disease-linked mutant presenilin-1. M Shimojo, N Sahara, M Murayama, H Ichinose, A Takashima, Neurosci Res 2007 57 446 453 10.1016/j.neures.2006.12.005 17210196 (Pubitemid 46283080)
12. Increased in vivo amyloid-β42 production, exchange and loss in presenilin mutation carriers. R Potter, BW Patterson, DL Elbert, V Ovod, T Kasten, W Sigurdson, K Mawuenyega, T Blazey, A Goate, R Chott, KE Yarasheski, DM Holtzman, JC Morris, TL Benzinger, RJ Bateman, Sci Transl Med 2013 5 189ra77 23761040
13. The mechanism of γ-secretase dysfunction in Alzheimer's disease. L Chávez-Gutiérrez, L Bammens, I Benilova, A Vandersteen, M Benurwar, M Borgers, S Lismont, L Zhou, S Van Cleynenbreugel, H Esselmann, J Wiltfang, L Serneels, E Karran, H Gijsen, J Schymkowitz, F Rousseau, K Broersen, B De Strooper, EMBO J 2012 31 2261 2274 10.1038/emboj.2012.79 22505025
14. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. M Ohno, EA Sametsky, LH Younkin, H Oakley, SG Younkin, M Citron, R Vassar, JF Disterhoft, Neuron 2004 41 27 33 10.1016/S0896-6273(03)00810-9 14715132 (Pubitemid 38071826)
15. Temporal memory deficitis in Alzheimer's mouse models: rescue by genetic deletion of BACE1. M Ohno, L Chang, W Tseng, H Oakley, M Citron, WL Klein, R Vassar, JF Disterhoft, Eur J Neurosci 2006 23 251 260 10.1111/j.1460-9568.2005. 04551.x 16420434
16. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. M Ohno, SL Cole, M Yasvoina, J Zhao, M Citron, R Berry, JF Disterhoft, R Vassar, Neurobiol Dis 2007 26 134 145 10.1016/j.nbd.2006.12. 008 17258906 (Pubitemid 46436493)
17. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. L McConlogue, M Buttini, JP Anderson, EF Brigham, KS Chen, SB Freedman, D Games, K Johnson-Wood, M Lee, M Zeller, W Liu, R Motter, S Sinha, J Biol Chem 2007 282 26326 26334 10.1074/jbc.M611687200 17616527 (Pubitemid 47443774)
18. Genetic reductions of β-site amyloid precursor protein-cleaving enzyme 1 and amyloid-β ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. L Devi, M Ohno, Eur J Neurosci 2010 31 110 118 10.1111/j.1460-9568.2009.07031.x 20092558
19. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. R Kimura, L Devi, M Ohno, J Neurochem 2010 113 248 261 10.1111/j.1471-4159.2010.06608.x 20089133
20. Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease. L Devi, M Ohno, Transl Psychiatry 2013 3 284 10.1038/tp.2013.59 23880880
21. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. H Yu, CA Saura, SY Choi, LD Sun, X Yang, M Handler, T Kawarabayashi, L Younkin, B Fedeles, MA Wilson, S Younkin, ER Kandel, A Kirkwood, J Shen, Neuron 2001 31 713 726 10.1016/S0896-6273(01)00417-2 11567612 (Pubitemid 32907369)
22. Reduced β-amyloid production and increased inflammatory responses in presenilin deficient knock-out mice. V Beglopoulos, X Sun, CA Saura, CA Lemere, RD Kim, J Shen, J Biol Chem 2004 279 46907 46914 10.1074/jbc.M409544200 15345711 (Pubitemid 39518343)
23. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. CA Saura, SY Choi, V Beglopoulos, S Malkani, D Zhang, BS Shankaranarayana Rao, S Chattarji 3rd, RJ Kelleher, ER Kandel, K Duff, A Kirkwood, J Shen, Neuron 2004 42 23 36 10.1016/S0896-6273(04)00182-5 15066262 (Pubitemid 38456965)
24. Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. K Tabuchi, G Chen, TC Sudhof, J Shen, J Neurosci 2009 29 7290 7301 10.1523/JNEUROSCI.1320-09.2009 19494151
25. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. I Dewachter, D Reversé N Caluwaerts, L Ris, C Kuipéri, C Van den Haute, K Spittaels, L Umans, L Serneels, E Thiry, D Moechars, M Mercken, E Godaux, F Van Leuven, J Neurosci 2002 22 3445 3453 11978821 (Pubitemid 37465750)
26. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. CA Saura, G Chen, S Malkani, SY Choi, RH Takahashi, D Zhang, GK Gouras, A Kirkwood, RG Morris, J Shen, J Neurosci 2005 25 6755 6764 10.1523/JNEUROSCI.1247-05.2005 16033885 (Pubitemid 41023143)
27. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. T Melnikova, S Fromholt, H Kim, D Lee, G Xu, A Price, BD Moore, TE Golde, KM Felsenstein, A Savonenko, DR Borchelt, J Neurosci 2013 33 3765 3779 10.1523/JNEUROSCI.4251-12.2013 23447589
28. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. B Sun, Y Zhou, B Halabisky, I Lo, SH Cho, S Mueller-Steiner, N Devidze, X Wang, A Grubb, L Gan, Neuron 2008 60 247 257 10.1016/j.neuron.2008.10.001 18957217
29. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioural deficits in a mouse model of Alzheimer's disease. H Fukumoto, H Takahashi, N Tarui, J Matsui, T Tomita, M Hirode, M Sagayama, R Maeda, M Kawamoto, K Hirai, J Terauchi, Y Sakura, M Kakihana, K Kato, T Iwatsubo, M Miyamoto, J Neurosci 2010 30 11157 11166 10.1523/JNEUROSCI.2884-10.2010 20720123
30. 2,2',4'-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. Z Zhu, C Li, X Wang, Z Yang, J Chen, L Hu, H Jiang, X Shen, J Neurochem 2010 114 374 385 10.1111/j.1471-4159.2010.06751.x 20412384
31. β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. WP Chang, X Huang, D Downs, JR Cirrito, G Koelsch, DM Holtzman, AK Ghosh, J Tang, FASEB J 2011 25 775 784 10.1096/fj.10-167213 21059748
32. Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2476 mouse model of Alzheimer's disease. TA Comery, RL Martone, S Aschmies, KP Atchison, G Diamantidis, X Gong, H Zhou, AF Kreft, MN Pangalos, J Sonnenberg-Reines, JS Jacobsen, KL Marquis, J Neurosci 2005 25 8898 8902 10.1523/JNEUROSCI.2693-05.2005 16192379 (Pubitemid 41384457)
33. Begacestat (GSI-953): a novel selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. RL Martone, H Zhou, K Atchison, T Comery, JZ Xu, X Huang, X Gong, M Jin, A Kreft, B Harrison, SC Mayer, S Aschmies, C Gonzales, MM Zaleska, DR Riddell, E Wagner, P Lu, SC Sun, J Sonnenberg-Reines, A Oganesian, K Adkins, MW Leach, DW Clarke, D Huryn, M Abou-Gharbia, R Magolda, J Bard, G Frick, S Raje, SB Forlow, et al. J Pharmacol Exp Ther 2009 331 598 608 19671883
34. Lowering β-amyloid levels rescues learning and memory in a Down syndrome mouse model. WJ Netzer, C Powell, Y Nong, J Blundell, L Wong, K Duff, M Flajolet, P Greengard, PLoS one 2010 5 10943 10.1371/journal.pone.0010943 20532168
35. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. Y Mitani, J Yarimizu, K Saita, H Uchino, H Akashiba, Y Shitaka, K Ni, N Matsuoka, J Neurosci 32 2037 2050 22323718
36. Amerlioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools. Y Mitani, J Yarimizu, H Akashiba, Y Shitaka, K Ni, N Matsuoka, J Neurochem 2013 125 465 472 10.1111/jnc.12125 23240999
37. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). T Iwatsubo, A Odaka, N Suzuki, H Mizusawa, N Nukina, Y Ihara, Neuron 1994 13 45 53 10.1016/0896-6273(94)90458-8 8043280
38. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. JP Cleary, DM Walsh, JJ Hofmeister, GM Shankar, MA Kuskowski, DJ Selkoe, KH Ashe, Nat Neurosci 2005 8 79 84 10.1038/nn1372 15608634 (Pubitemid 41236735)
39. A specific amyloid-β protein assembly in the brain impairs memory. S Lesné MT Koh, L Kotilinek, R Kayed, CG Glabe, A Yang, M Gallagher, KH Ashe, Nature 2006 440 352 357 10.1038/nature04533 16541076
40. Interaction between Aβ(1-42) and Aβ(1-40) in Alzheimer's β-amyloid formation in vitro. K Hasegawa, I Yamaguchi, S Omata, F Gejyo, H Naiki, Biochemistry 1999 38 15514 15521 10.1021/bi991161m 10569934 (Pubitemid 129503592)
41. Aβ40 protects non-toxic Aβ42 monomer from aggregation. Y Yan, C Wang, J Mol Biol 2007 369 909 916 10.1016/j.jmb.2007.04.014 17481654 (Pubitemid 46754070)
42. Amyloid β protein: Aβ40 inhibits Aβ42 oligomerization. MM Murray, SL Bernstein, V Nyugen, MM Condron, DB Teplow, MT Bowers, J Am Chem Soc 2009 131 6316 6317 10.1021/ja8092604 19385598
43. H Watanabe, F Bernier, T Miyagawa, A Therapeutic Agent for Aβ Related Disorders Patent publication WO2006/112552 24587892
44. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. I Kuperstein, K Broersen, I Benilova, J Rozenski, W Jonckheere, M Debulpaep, A Vandersteen, I Segers-Nolten, K Van Der Werf, V Subramaniam, D Braeken, G Callewaert, C Bartic, R D'Hooge, IC Martins, F Rousseau, J Schymkowitz, B De Strooper, EMBO J 2010 29 3408 3420 10.1038/emboj.2010.211 20818335
45. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired γ-secretase activity and exacerbated amyloid pathology. Y Deng, L Tarassishin, V Kallhoff, E Peethumnongsin, L Wu, YM Li, H Zheng, J Neurosci 2006 26 3845 3854 10.1523/JNEUROSCI.5384-05.2006 16597739
46. Aβ40 inhibits amyloid deposition in vivo. J Kim, L Onstead, S Randle, R Price, L Smithson, C Zwizinski, DW Dickson, T Golde, E McGowan, J Neurosci 2007 27 627 633 10.1523/JNEUROSCI.4849-06.2007 17234594 (Pubitemid 46143766)
47. Normal cognition in transgenic BRI2-Aβ mice. J Kim, P Chakrabarty, A Hanna, A March, DW Dickson, DR Borchelt, T Golde, C Janus, Mol Neurodegen 2013 8 15 10.1186/1750-1326-8-15
48. Modulation of gamma-secretase for the treatment of Alzheimer's disease. B Tate, TD McKee, RM Loureiro, JA Dumin, W Xia, K Pojasek, WF Austin, NO Fuller, JL Hubbs, R Shen, J Jonker, J Ives, B Bronk, Int J Alzheimer Dis 2012 2012 210756
49. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioural deficits in Tg2576 mice. K Rogers, KM Felsenstein, L Hrdlicka, Z Tu, F Albayya, W Lee, S Hopp, MJ Miller, D Spaulding, Z Yang, H Hodgdon, S Nolan, M Wen, D Costa, JF Blain, E Freeman, B De Strooper, V Vulsteke, L Scrocchi, H Zetterberg, E Portelius, B Hutter-Paier, D Havas, M Ahlijanian, D Flood, L Leventhal, G Shapiro, H Patzke, R Chesworth, G Koenig, Mol Neurodegen 2012 7 61 10.1186/1750-1326-7-61
50. 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. BP Imbimbo, E Del Giudice, D Colavito, A D'Arrigo, M Dalle Carbonare, G Villetti, F Facchinetti, R Volta, V Pietrini, MF Baroc, L Serneels, B De Strooper, A Leon, J Pharmacol Exp Ther 2007 323 822 830 10.1124/jpet.107.129007 17895400 (Pubitemid 350146064)
51. In vitro and in vivo profiling of CHF5022 and CHF5074, two β-amyloid1-42 lowering agents. BP Imbimbo, E Del Giudice, V Cenacchi, R Volta, G Villetti, F Facchinetti, B Riccardi, P Puccini, N Moretto, F Grassi, S Ottonello, A Leon, Pharmacol Res 2007 55 318 328 10.1016/j.phrs.2006.12.010 17292621 (Pubitemid 46533934)
52. CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. BP Imbimbo, B Hutter-Paier, G Villetti, F Facchinetti, V Cenacchi, R Volta, A Lanzillotta, M Pizzi, M Windisch, Brit J Pharmacol 2009 156 982 993 10.1111/j.1476-5381.2008.00097.x
53. CHF5074, a novel γ-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. BP Imbimbo, L Giardino, S Sivilia, A Giuliani, M Gusciglio, V Pietrini, E Del Giudice, A D'Arrigo, A Leon, G Villetti, L Calzà J Alzheimer Dis 2010 20 159 173
54. Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. MZ Kounnas, AM Danks, S Cheng, C Tyree, E Ackerman, X Zhang, K Ahn, P Nguyen, D Comer, L Mao, C Yu, D Pleynet, PJ Digregorio, G Velicelebi, KA Stauderman, WT Comer, WC Mobley, YM Li, SS Sisodia, RE Tanzi, SL Wagner, Neuron 2010 67 769 780 10.1016/j.neuron.2010.08. 018 20826309
55. Chronic treatment with a novel γ-secretase modulator, JNJ40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. B Van Broeck, JM Chen, G Tréton, M Desmidt, C Hopf, N Ramsden, E Karran, M Mercken, A Rowley, Br J Pharmacol 2011 163 375 389 10.1111/j.1476-5381.2011. 01207.x 21232036
56. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. KE Wisniewski, A Boutajangout, Brain Struct Funct 2010 214 201 218 10.1007/s00429-009-0236-2 20012091
57. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. PS Aisen, B Vellas, H Harald, Nat Rev Drug Disc 2013 12 324 10.1038/nrd3842-c1
58. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. CR Jack Jr, VJ Lowe, SD Weigand, HJ Wiste, ML Senjem, DS Knopman, MM Shiung, JL Gunter, BF Boeve, BJ Kemp, M Weiner, RC Petersen, Alzheimer's Disease Neuroimaging Initiative, Brain 2009 132 1355 1365 10.1093/brain/awp062 19339253
59. Brain β-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. CR Jack Jr, HJ Wiste, P Vemuri, SD Weigand, ML Senjem, G Zeng, MA Bernstein, JL Gunter, VS Pankratz, PS Aisen, MW Weiner, RC Petersen, LM Shaw, JQ Trojanowski, DS Knopman, Alzheimer's Disease Neuroimaging Initiative, Brain 2010 133 3336 3348 10.1093/brain/awq277 20935035
60. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. CR Jack Jr, DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, RC Petersen, JQ Trojanowski, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09) 70299-6 20083042
61. Evidence for ordering of Alzheimer disease biomarkers. CR Jack Jr, P Vemuri, HJ Wiste, SD Weigand, PS Aisen, JQ Trojanowski, LM Shaw, MA Bernstein, RC Petersen, MW Weiner, DS Knopman, Alzheimer's Disease Neuroimaging Initiative, Arch Neurol 2011 68 1526 1535 10.1001/archneurol.2011.183 21825215
62. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. CR Jack Jr, P Vemuri, HJ Wiste, SD Weigand, TG Lesnick, V Lowe, K Kantarci, MA Bernstein, ML Senjem, JL Gunter, BF Boeve, JQ Trojanowski, LM Shaw, PS Aisen, MW Weiner, RC Petersen, DS Knopman, Alzheimer's Disease Neuroimaging Initiative, Arch Neurol 2012 69 856 867 22409939
63. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. P Buchhave, L Minthon, H Zetterberg, AK Wallin, K Blennow, O Hansson, Arch Gen Psychiatry 2012 69 98 106 10.1001/archgenpsychiatry.2011.155 22213792
64. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. RJ Bateman, C Xiong, TL Benzinger, AM Fagan, A Goate, NC Fox, DS Marcus, NJ Cairns, X Xie, TM Blazey, DM Holtzman, A Santacruz, V Buckles, A Oliver, K Moulder, PS Aisen, B Ghetti, WE Klunk, E McDade, RN Martins, CL Masters, R Mayeux, JM Ringman, MN Rossor, PR Schofield, RA Sperling, S Salloway, JC Morris, Dominantly Inherited Alzheimer Network, N Engl J Med 2012 367 795 804 10.1056/NEJMoa1202753 22784036
65. Sting of Alzheimer's failures offset by upcoming prevention trials. A Mullard, Nat Rev Drug Disc 2012 11 657 660 10.1038/nrd3842
66. Can we prevent Alzheimer's disease? Secondary 'prevention' trials in Alzheimer's disease. MC Carrillo, HR Brashear, V Logovinsky, JM Ryan, HH Feldman, ER Siemers, S Abushakra, DM Hartley, RC Petersen, AS Khachaturian, RA Sperling, Alzheimers Dement 2013 9 123 131 10.1016/j.jalz.2012.12.004 23411394
67. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. N Mattsson, E Portelius, S Rolstad, M Gustavsson, U Andreasson, M Stridsberg, A Wallin, K Blennow, H Zetterberg, J Alzheimer Dis 2012 30 767 778
68. Prediction of dementia in MCI patients based on core diagnostic markers forAlzheimer disease. A Prestia, A Caroli, WM van der Flier, R Ossenkoppele, B Van Berckel, F Barkhof, CE Teunissen, AE Wall, SF Carter, M Schöll, IH Choo, A Nordberg, P Scheltens, GB Frisoni, Neurology 2013 80 1048 1056 10.1212/WNL.0b013e3182872830 23390179
69. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. I Benilova, E Karran, B De Strooper, Nat Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
70. CSF Aβ as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses. Y Lu, D Riddell, E Hajos-Korcsok, K Bales, KM Wood, CE Nolan, AE Robshaw, L Zhang, L Leung, SL Becker, E Tseng, J Barricklow, EH Miller, S Osgood, BT O'Neill, MA Brodney, DS Johnson, M Pettersson, J Pharmacol Exp Ther 2012 342 366 375 10.1124/jpet.112.192625 22562771
71. Fluid biomarkers in Alzheimer disease. K Blennow, H Zetterberg, AM Fagan, Cold Spring Harb Perspectives Med 2012 2 006221
72. Is Aβ a sufficient biomarker for monitoring anti-Aβ clinical studies? A critical review. J Moreth, C Mavoungou, K Schindowski, Front Aging Neurosci 2013 5 25 23847530
73. Progress update: fluid and imaging biomarkers in Alzheimer's disease. CL Sutphen, AM Fagan, DM Holtzman, Biol Psychiatry 2013 doi.org/10.1016/j.biopsych. 2013.07.031 24582164
74. Effect of immmunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. K Blennow, H Zetterberg, JO Rinne, S Salloway, J Wei, R Black, M Grundman, E Liu, AAB-001 201/202 Investigators, Arch Neurol 2012 69 1002 1010 10.1001/archneurol.2012.90 22473769
75. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. K Blennow, H Hampel, H Zetterberg, Neuropsychopharmacology Rev 2013 10.1038/npp.2013.154
76. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that 129/SVE mouse is a suitable preclinical pharmacology model for identifying small molecule gamma secretase inhibitors. Y Lu, L Zhang, CE Nolan, SL Becker, K Atchison, AE Robshaw, LR Pustilnik, SM Osgood, EH Miller, AF Stepan, C Subramanyam, I Efremov, AJ Hallgren, D Riddell, J Pharmacol Exp Ther 2011 339 922 934 21930801
77. The dynamics of Aβ distribution after γ-secretatse inhibitor treatment, as determined by experimental and modeling approaches in a wild type rat. LM Tai, H Jacobsen, L Ozmen, A Flohr, R Jakob-Roetne, A Caruso, HP Grimm, J Pharmacokinet Pharmacodyn 2012 229 227 237
78. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. CF Albright, RC Dockens, JE Meredith Jr, RE Olson, R Slemmon, KA Lentz, JS Wang, RR Denton, G Pilcher, PW Rhyne, JJ Raybon, DM Barten, C Burton, JH Toyn, S Sankaranarayanan, C Polson, V Guss, R White, F Simutis, T Sanderson, KW Gillman, JE Starrett Jr, J Bronson, O Sverdlov, SP Huang, L Castaneda, H Feldman, V Coric, R Zaczek, JE Macor, et al. J Pharmacol Exp Ther 2013 344 686 695 23275065
79. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators. H Borghys, M Tuefferd, B Van Broeck, E Clessens, L Dillen, W Cools, P Vinken, R Straetemans, F De Ridder, H Gijsen, M Mercken, J Alzheimer Dis 2012 28 809 822
80. Dynamics of Aβ 42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10 h. J Hawkins, DC Harrison, S Ahmed, RP Davis, T Chapman, I Marshall, B Smith, TL Mead, A Medhurst, GM Giblin, A Hall, MI Gonzalez, J Richardson, I Hussain, Neurodegen Dis 2011 8 455 464 10.1159/000324511
81. In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel β-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat. JD Best, MT Jay, F Otu, I Churcher, M Reilly, P Morentin-Gutierrez, C Pattison, T Harrison, MS Shearman, JR Atack, J Pharmacol Exp Ther 2006 317 786 790 10.1124/jpet.105.100271 16443723
82. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. PC May, RA Dean, SL Lowe, F Martenyi, SM Sheehan, LN Boggs, SA Monk, BM Mathes, DJ Mergott, BM Watson, SL Stout, DE Timm, E Smith Labell, CR Gonzales, M Nakano, SS Jhee, M Yen, L Ereshefsky, TD Lindstrom, DO Calligaro, PJ Cocke, D Greg Hall, S Friedrich, M Citron, JE Audia, J Neurosci 2011 31 16507 16516 10.1523/JNEUROSCI.3647-11.2011 22090477
83. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing. X Liu, H Wong, K Scearce-Levie, RJ Watts, M Coraggio, YG Shin, K Peng, KR Wildsmith, JK Atwal, J Mango, SP Schauer, K Regal, KW Hunt, AA Thomas, M Siu, J Lyssikatos, G Deshmukh, CE Hop, Drug Metab DispositionClin Drug Invest 2013 41 1319 1328
84. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men. G Tong, L Castaneda, JS Wang, O Sverdlov, SP Huang, R Slemmon, H Gu, O Wong, H Li, RM Berman, C Smith, C Albright, RC Dockens, Clin Drug Invest 2012 32 761 769 10.1007/s40261-012-0006-4
85. Placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. R Dockens, JS Wang, L Castaneda, O Sverdlov, SP Huang, R Slemmon, H Gu, O Wong, H Li, RM Berman, C Smith, CF Albright, G Tong, Clin Pharmacokinet 2012 51 681 693 10.1007/s40262-012-0005-x 23018531
86. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. V Coric, CH van Dyck, S Salloway, N Andreasen, M Brody, RW Richter, H Soininen, S Thein, T Shiovitz, G Pilcher, S Colby, L Rollin, R Dockens, C Pachai, E Portelius, U Andreasson, K Blennow, H Soares, C Albright, HH Feldman, RM Berman, Arch Neurol 2012 69 1430 1440 10.1001/archneurol.2012.2194 22892585
87. Amyloid in neurodegenerative diseases: friend or foe? KF Wolfe, DM Cyr, Sem Cell Dev Biol 2011 22 476 481 10.1016/j.semcdb.2011.03.011
88. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. TL Spires, M Meyer-Luehmann, EA Stern, PJ McLean, J Skoch, PT Nguyen, BJ Bacskai, BT Hyman, J Neurosci 2005 31 7278 7287 (Pubitemid 41113944)
89. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. M Meyer-Luehmann, TL Spires-Jones, C Prada, M Garcia-Alloza, A de Calignon, A Rozkalne, J Koenigsknecht-Talboo, DM Holtzman, BJ Bacskai, BT Hyman, Nature 2008 451 720 724 10.1038/nature06616 18256671 (Pubitemid 351220570)
90. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. H Xie, J Guan, LA Borrelli, J Xu, A Serrano-Pozo, BJ Bacskai, J Neurosci 2013 43 17042 17051
91. Amyloid deposition is associated with impaired default network function in older persons without dementia. RA Sperling, PS Laviolette, K O'Keefe, J O'Brien, DM Rentz, M Pihlajamaki, G Marshall, BT Hyman, DJ Selkoe, T Hedden, RL Buckner, JA Becker, KA Johnson, Neuron 2009 63 178 188 10.1016/j.neuron.2009.07. 003 19640477
92. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. YI Sheline, ME Raichle, AZ Snyder, JC Morris, D Head, S Wang, MA Mintun, Biol Psychiatry 2010 67 584 587 10.1016/j.biopsych. 2009.08.024 19833321
93. Aβ species removal after Aβ42 immunization. JA Nicoll, E Barton, D Boche, JW Neal, I Ferrer, P Thompson, C Vlachouli, D Wilkinson, A Bayer, D Games, P Seubert, D Schenk, C Holmes, J Neuropath Exp Neurol 2006 11 1040 1048
94. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. C Holmes, D Boche, D Wilkinson, G Yadegarfar, V Hopkins, A Bayer, RW Jones, R Bullock, S Love, JW Neal, E Zotova, JA Nicoll, Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 (Pubitemid 351978111)
95. Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. S Hong, O Quintero-Monzon, BL Ostaszewski, DR Podlisny, WT Cavanaugh, T Yang, DM Holtzman, JR Cirrito, DJ Selkoe, J Neurosci 2011 31 15861 15869 10.1523/JNEUROSCI.3272-11.2011 22049429
96. Antibody capture of soluble Aβ does not reduce cortical Aβ amyloidosis in the PDAPP mouse. P Seubert, R Barbour, K Khan, R Motter, P Tang, D Kholodenko, K Kling, D Schenk, K Johnson-Wood, S Schroeter, D Gill, JS Jacobsen, M Pangalos, G Basi, D Games, Neurodegenerative Dis 2008 5 65 71 10.1159/000112834
97. Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. JR Walker, R Pacoma, J Watson, W Ou, J Alves, DE Mason, EC Peters, HD Urbina, G Welzel, A Althage, B Liu, T Tuntland, LH Jacobson, JL Harris, AM Schumacher, J Neurosci 2013 6 2457 2464
98. Consistency of BACE inhibitor-mediated brain amyloid production inhibition by MK-8931 in Alzheimer's patients and healthy young adults. J Stone, HJ Kleijn, M Dockendorf, L Ma, J Palcza, J Tseng, M Tanen, M Forman, Alzheimers Dementia 2013 9 Suppl 690 P691
99. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease. MS Forman, HJ Kleijn, M Dockendorf, J Palcza, J Tseng, C Canales, M Egan, M Kennedy, O Laterza, L Ma, J Scott, M Tanen, J Apter, M Backonja, L Ereshefsky, H Gevorkyan, S Jhee, R Rynders, A Zari, E Bryan, J Wagner, M Troyer, J Stone, Alzheimers Dementia 2013 9 Suppl 139
100. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. JO Rinne, DJ Brooks, MN Rossor, NC Fox, R Bullock, WE Klunk, CA Mathis, K Blennow, J Barakos, AA Okello, S Rodriguez Martinez De Liano, E Liu, M Koller, KM Gregg, D Schenk, R Black, M Grundman, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
101. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. S Ostrowitzki, D Deptula, L Thurfjell, F Barkhof, B Bohrmann, DJ Brooks, WE Klunk, E Ashford, K Yoo, ZX Xu, H Loetscher, L Santarelli, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
102. Safety, tolerability and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of γ-secretase. ER Siemers, RA Dean, S Friedrich, L Ferguson-Sells, C Gonzales, MR Farlow, PC May, Clin Neuropharmacol 2007 30 317 325 10.1097/WNF.0b013e31805b7660 18090456 (Pubitemid 350307310)
103. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. ER Siemers, JF Quinn, J Kaye, MR Farlow, A Porsteinsson, P Tariot, P Zoulnouni, JE Galvin, DM Holtzman, DS Knopman, J Satterwhite, C Gonzales, RA Dean, PC May, Neurology 2006 66 602 604 10.1212/01.WNL.0000198762.41312.E1 16505324 (Pubitemid 43739900)
104. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, MR Farlow, JE Galvin, ER Peskind, JF Quinn, A Sherzai, BB Sowell, PS Aisen, LJ Thal, Arch Neurol 2008 65 1031 1038 18695053
105. A β-secretase inhibitor decreases amyloid-β production in the central nervous system. RJ Bateman, ER Siemers, KG Mawuenyega, G Wen, KR Browning, WC Sigurdson, KE Yarasheski, SW Friedrich, RB Demattos, PC May, SM Paul, DM Holtzman, Ann Neurol 2009 66 48 54 10.1002/ana.21623 19360898
106. A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease. E Portelius, RA Dean, MK Gustavsson, U Andreasson, H Zetterberg, E Siemers, K Blennow, Alzheimer Res Ther 2010 2 7 10.1186/alzrt30
107. Amyloid-β1-15/16 as a marker for γ-secretase inhibition in Alzheimer's disease. E Portelius, H Zetterberg, RA Dean, A Marcil, P Bourgeois, M Nutu, U Andreasson, E Siemers, KG Mawuenyega, WC Sigurdson, PC May, SM Paul, DM Holtzman, K Blennow, RJ Bateman, J Alzheimer Dis 2012 31 335 341
108. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. RS Doody, R Raman, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, F He, X
109. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. RC Green, LS Schneider, DA Amato, AP Beelen, G Wilcock, EA Swabb, KH Zavitz, Tarenflurbil Phase 3 Study Group, JAMA 2009 302 2557 2564 10.1001/jama.2009.1866 20009055
110. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. JL Eriksen, SA Sagi, TE Smith, S Weggen, P Das, DC McLendon, VV Ozols, KW Jessing, KH Zavitz, EH Koo, TE Golde, J Clin Invest 2003 112 440 449 10.1172/JCI200318162 12897211 (Pubitemid 38063773)
111. Lack of specific amyloid-β(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. TA Lanz, GJ Fici, KM Merchant, J Pharmacol Exp Ther 2005 312 399 406 15340006 (Pubitemid 40096494)
112. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. J Ross, S Sharma, J Winston, M Nunez, G Bottini, M Franceschi, E Scarpini, E Frigerio, F Fiorentini, M Fernandez, S Sivilia, L Giardino, L Calza, D Norris, H Cicirello, D Casula, BP Imbimbo, Curr Alzheimer Res 2013 10 742 753 10.2174/13892037113149990144 23968157
113. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012. M Pettersson, AF Stepan, GW Kauffman, DS Johnson, Expert Opin Ther Pat 2013 23 1349 1366 10.1517/13543776.2013.821465 23875696
114. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mice. D Schenk, R Barbour, W Dunn, G Gordon, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, Z Liao, I Lieberburg, R Motter, L Mutter, F Soriano, G Shopp, N Vasquez, C Vandevert, S Walker, M Wogulis, T Yednock, D Games, P Seubert, Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
115. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. S Gilman, M Koller, RS Black, L Jenkins, SG Griffith, NC Fox, L Eisner, L Kirby, MB Rovira, F Forette, JM Orgogozo, AN1792(QS-21)-201 Study Team, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
116. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. S Salloway, R Sperling, NC Fox, K Blennow, W Klunk, M Raskind, M Sabbagh, LS Honig, AP Porsteinsson, S Ferris, M Reichert, N Ketter, B Nejadnik, V Guenzler, M Miloslavsky, D Wang, Y Lu, J Lull, IC Tudor, E Liu, M Grundman, E Yuen, R Black, HR Brashear, Bapineuzumab 301 and 302 Clinical Trial Investigators, N Engl J Med 2014 370 322 333 10.1056/NEJMoa1304839 24450891
117. Phase 3 trials of solanezumab for mold-to-moderate Alzheimer's disease. RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, R Raman, X Sun, PS Aisen, E Siemers, H Liu-Seifert, R Mohs, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group, N Engl J Med 2014 370 311 321 10.1056/NEJMoa1312889 24450890
118. Insights into the mechanisms of action of anti-Aβ antibodies in Alzheimer's disease mouse models. Y Levites, LA Smithson, RW Price, RS Dakin, B Yuan, MR Sierks, J Kim, E McGowan, DK Reed, TL Rosenberry, P Das, TE Golde, FASEB J 2006 20 2002 E2014
119. Quantitative and mechanistic studies of Aβ immunotherapy. T Golde, P Das, Y Levites, CNS Neurol Disord Drug Targets 2009 8 31 49 10.2174/187152709787601830 19275635
120. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. RB Demattos, J Lu, Y Tang, MM Racke, CA Delong, JA Tzaferis, JT Hole, BM Forster, PC McDonnell, F Liu, RD Kinley, WH Jordan, ML Hutton, Neuron 2012 76 908 920 10.1016/j.neuron.2012.10.029 23217740
121. Effects of bapineuzumab on CSF p-Tau and t-Tau in mild-to-moderate Alzheimer's disease: results from two phase III trials in APO-4 carriers and non-carriers. JR Streffer, K Blennow, S Salloway, H Zetterberg, Y-Z Xu, Y Lu, J Lull, P Collins, IC Tudor, K Gregg, S Styren, E Yuen, M Grundman, RH Brashear, E Liu, Alzheimers Dementia 2013 9 Suppl 138
122. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. M Farlow, SE Arnold, CH van Dyck, PS Aisen, BJ Snider, AP Porsteinsson, S Friedrich, RA Dean, C Gonzales, G Sethuraman, RB DeMattos, R Mohs, SM Paul, ER Siemers, Alzheimers Dement 2012 8 261 271 10.1016/j.jalz.2011.09.224 22672770
123. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. L Puli, Y Pomeshchik, K Olas, T Malm, J Koistinaho, H Tanila, J Neuroinflam 2012 9 105 10.1186/1742-2094-9-105
124. Intracranial injection of gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. TL Sudduth, A Greenstein, DM Wilcock, J Neurosci 2013 33 9684 9692 10.1523/JNEUROSCI.1220-13.2013 23739965
125. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. NR Relkin, P Szabo, B Adamiak, T Burgut, C Monthe, RW Lent, S Younkin, L Younkin, R Schiff, ME Weksler, Neurobiol Aging 2009 30 1728 1736 10.1016/j.neurobiolaging.2007.12.021 18294736
126. Intravenous immunoglobulin for treatment of mild-to moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. R Dodel, A Rominger, P Bartenstein, F Barkhof, K Blennow, S Förster, Y Winter, JP Bach, J Popp, J Alferink, J Wiltfang, K Buerger, M Otto, P Antuono, M Jacoby, R Richter, J Stevens, I Melamed, J Goldstein, S Haag, S Wietek, M Farlow, F Jessen, Lancet Neurol 2013 12 233 243 10.1016/S1474-4422(13) 70014-0 23375965
127. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ O Adolfsson, M Pihlgren, N Toni, Y Varisco, AL Buccarello, K Antoniello, S Lohmann, K Piorkowska, V Gafner, JK Atwal, J Maloney, M Chen, A Gogineni, RM Weimer, DL Mortensen, M Friesenhahn, C Ho, R Paul, A Pfeifer, A Muhs, RJ Watts, J Neurosci 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
128. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β B Bohrmann, K Baumann, J Benz, F Gerber, W Huber, F Knoflach, J Messer, K Oroszlan, R Rauchenberger, WF Richter, C Rothe, M Urban, M Bardroff, M Winter, C Nordstedt, H Loetscher, J Alzheimer Dis 2011 26 1 21